Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week

Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week

Teva is launching an exclusive generic to Gilead's Viread in the U.S.

Amid the turmoil of massive jobs cuts, Teva Pharmaceutical was able to put out a piece of good news on Friday. It's launching an exclusive generic to Gilead Sciences' hepatitis B and HIV antiviral Viread, a product the company says pulled in about $750 million over the last year.